The mandate applies to oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine and fentanyl.
The DEA publicly proposed the quotas Aug. 7 and invited comments on the proposal through Sept. 6. The agency received more than 100 comments expressing concern that the proposed reduction would adversely affect the availability of opioid medication for patients with chronic pain. However, the agency believes the new manufacturing quotas will still satisfy demand, while also reducing drug diversion.
“These comments were general in nature, and raised issues of specific medical illnesses and medical treatment, and therefore are outside of the scope of this final order for 2018,” wrote the DEA in its final order. “As a result, these 106 comments did not provide new discrete data for consideration, and do not impact the original analysis involved in establishing the 2018 aggregate production quotas.”
To read the DEA final order, click here.
More articles on opioids:
1 in 6 ER visits in Q2 were opioid related
How community pharmacists are fighting the opioid epidemic
Study: 61% of opioid overdoses occur among chronic pain patients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
